Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
A Connected Healthcare Ecosystem
A look at the future of Healthcare.
Stakeholders across the healthcare continuum are talking about the benefits and challenges involved with a new model: connected health. There are varying definitions as to what connected health, and its various components, entail. The analysts at Accenture describe connected health as healthcare delivery that leverages the systematic application of healthcare IT to facilitate the accessing and sharing of information, as well as subsequent analysis of health data across healthcare systems. Connected health encourages communication and collaboration among all of the various stakeholders involved in a patient’s health. It uses knowledge and technology in new ways for more effective, efficient, and affordable healthcare.
At the center of this, and other definitions, is the patient. This movement toward a more patient-centric healthcare model and away from a pill-based one has been ongoing for several years. It’s just more recently, however, due to technological advances that theoretical integration could become a reality.
Experts in the area say the value of connected health is optimized through the coordinated efforts of many stakeholders — the clinician, the organization/system, the patient, the insurer or payer, and the wider population or society as a whole. Furthermore, analysts say the greatest value of connected health lies in the long-term changes to clinical processes and health that the stages of HIE and application of health information analytics bring.
But connected health goes beyond simply managing and analyzing patients’ clinical data. Accenture says connected health encourages communication and collaboration among all the stakeholders involved in a patient’s health to get to improved care — and better health outcomes — at lower costs.
Connected health will produce other disruptions across the biopharma value chain. McKinsey analysts say Internet communications will give rise to open platforms that will create new models for R&D and manufacturing. These virtual workplaces will invite open collaboration among biopharma companies, academics, clinical-research organizations, and even contract manufacturers. Incumbents may perceive the new models as threats that challenge the status quo and allow competition from new entrants with more capital-efficient business models. But these new models can also create opportunities for innovative incumbents to bring products to market faster, and to manufacture, market, and distribute products at lower levels of investment.
This special issue is intended to incite the important conversations that need to happen to realize the benefits that connected health can bring to bear for all stakeholders, but most importantly patients.
In addition, we encourage you to visit our digital edition to access a special ebook — Connected Health Transforms Management of Health and Chronic Conditions — to learn more about the role life-sciences companies play in this evolving marketplace.
COMING IN APRIL 2014
-Start-Ups: The Entrepreneur’s Journey
-The Patient Experience
-The Role of the NIH
-Economic Development Centers
-Creating Effective FDA Communications
-C-Suite — CROs
-Market Focus — Indonesia
-Showcase Feature — Mobile
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh
Managing Editor Denise Myshko
Senior Editor Robin Robinson
Editor Kim Ribbink
Design associate Ariel Medel
National account manager Cathy Tracy
WEBCAST?NETWORK?PRODUCER Daniel Limbach
CIRCULATION Assistant Kathy Deiuliis
Copyright 2014 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Fourteen, Number Three PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O.?Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.
Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.
PharmaVoice Coverage and Distribution: Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.
Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: firstname.lastname@example.org.
Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: email@example.com.
Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.
Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O.?Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: firstname.lastname@example.org. Volume 14 • Number 3
Their Word… Denise Myshko Managing Editor Connected health encourages communication and collaboration among all of the various stakeholders involved in a patient’s health. The goal: higher quality, more accessible, and cost-effective healthcare.
Robin Robinson Senior Editor Today, the vision for connected health is being shared by all stakeholders along the healthcare continuum and this impetus will someday create a totally integrated healthcare system that improves care and reduces costs.
Send your letters to email@example.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.